CD4 and neoplasm: It has been demonstrated that blockade of the PD-1/PD-L1 axis causes reversal of the immunosuppressive phenotype, activates the adaptive immune system, triggers tumor antigen recognition, activates cytotoxic CD4+ and CD8+ T cells, and enhances antitumor efficacy.